More antibiotic development needed, warns UK's HPA

21 September 2008

Ahead of its annual conference, the UK's Health Protection Agency issued a warning about the need for new antibiotics to be developed to ensure the range of treatment options for some infections does not run out. Alongside new development, other crucial factors in battling the war over so called "superbugs" include more careful prescribing, better infection control and general awareness among the health profession and public about appropriate antibiotic use.

According to David Livermore, an expert at the Agency, "the news relating to antibiotic resistance is currently a mixed picture. The good news is that we have more treatment options available for what we call Gram-positive bacteria, for example with methicillin-resistant Staphylococcus aureus there are several antibiotics to choose from and a number of new options in the advance stages of development."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK